Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab maintenance for advanced adrenocortical carcinoma
2024-520449-21-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and mitotane in adrenal cancer (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: authorised.
02
Drugs
cemiplimabmitotane
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2024-520449-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520449-21-00.